Compare
Can-Fite BioPharma Ltd. vs Medicinova Inc vs Scienture Holdings, Inc. vs Provectus Biopharmaceuticals, Inc.
| Latest fiscal year | Can-Fite BioPharma Ltd. CANF | Medicinova Inc MNOV | Scienture Holdings, Inc. SCNX | Provectus Biopharmaceuticals, Inc. PVCT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $405.0K | $409.7K | $431.6K | $336.1K |
| Revenue growth (YoY) | -39.9% | n/a | +215.9% | -45.5% |
| Gross margin | n/a | n/a | 76.8% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$9.83M | -$12.00M | -$41.51M | -$5.43M |
| EPS (Diluted) | -$5.97 | -$0.24 | -$2.70 | -$0.01 |
| Operating cash flow | -$8.95M | -$9.81M | -$13.38M | -$3.33M |
| Free cash flow | -$8.95M | -$9.81M | n/a | n/a |
| Cash & equivalents | $5.53M | $30.81M | $6.66M | $251.3K |
| Total assets | $9.51M | $45.60M | $84.18M | $697.5K |
| Total liabilities | n/a | $4.02M | $14.06M | $7.00M |
| Shareholders' equity | $5.59M | $41.59M | $70.12M | -$6.30M |
| Return on year-end equity | -175.8% | -28.9% | -59.2% | n/a |
| Shares outstanding | 2.62M | 49.22M | 40.63M | 420.28M |
Revenue, most recent five fiscal years
| Fiscal year | Can-Fite BioPharma Ltd. | Medicinova Inc | Scienture Holdings, Inc. | Provectus Biopharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $405.0K Ended 2025-12-31 | $409.7K Ended 2025-12-31 | $431.6K Ended 2025-12-31 | $336.1K Ended 2025-12-31 |
| 1 year earlier | $674.0K Ended 2024-12-31 | n/a | $136.6K Ended 2024-12-31 | $617.1K Ended 2024-12-31 |
| 2 years earlier | $743.0K Ended 2023-12-31 | $1.00M Ended 2023-12-31 | $1.36M Ended 2023-12-31 | $557.7K Ended 2023-12-31 |
| 3 years earlier | $810.0K Ended 2022-12-31 | n/a | $10.25M Ended 2022-12-31 | $989.0K Ended 2022-12-31 |
| 4 years earlier | $853.0K Ended 2021-12-31 | $4.04M Ended 2021-12-31 | $9.89M Ended 2021-12-31 | n/a |